Muvagyn

Lactobacillus gasseri DSM 14869 and Lactobacillus rhamnosus DSM 14870, the active ingredients in Muvagyn, are probiotics presented as a vaginal probiotic preparation for vaginal use. They aim to support normal vaginal flora and help reduce symptoms of dysbiosis in women. These strains colonize the vaginal mucosa, producing lactic acid and hydrogen peroxide that maintain an acidic environment and inhibit pathogenic microorganisms. The product is available over the counter in the European market.

GNH USA supplies Muvagyn as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Muvagyn is used to address conditions affecting the vaginal microbiome.

- Bacterial vaginosis: helps restore a healthy lactobacilli balance and may lower recurrence rates. - Vulvovaginal candidiasis (adjunct): supports normal flora alongside antifungal therapy. - Post‑antibiotic vaginal dysbiosis: aids re‑colonisation of beneficial bacteria after systemic antibiotic treatment.

Muvagyn is generally well tolerated, but some users may experience local reactions.

Common Side Effects: - Mild vaginal irritation or burning. - Increased vaginal discharge of a whitish or milky consistency. - Itching or pruritus localized to the vulvar area. - Transient odor change during initial colonisation. - Slight spotting after insertion. - Sensation of fullness or pressure.

Serious or Rare Side Effects: - Allergic reaction presenting as rash, swelling, or difficulty breathing. - Rare systemic infection in severely immunocompromised individuals. - Persistent severe vaginal pain or ulceration. - Unexplained fever or chills after use. - Severe inflammation requiring medical evaluation. - Anaphylaxis (extremely rare).

Before using Muvagyn, consider the following safety measures.

- Pregnancy: safety not established; consult a healthcare professional. - Breastfeeding: limited data; use only if advised by a clinician. - Known allergy to lactobacilli: avoid product. - Immunocompromised patients: use with caution and under medical supervision. - Concurrent antibiotic therapy: may reduce probiotic viability; timing adjustment may be needed. - Store at room temperature: keep in the original package, protect from moisture and direct heat.

Muvagyn may interact with other agents that affect vaginal flora.

Major Interactions (Avoid): - Broad‑spectrum antibiotics: can diminish probiotic viability and effectiveness. - Antifungal agents used concurrently: may interfere with colonisation of lactobacilli.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: increased risk of opportunistic infection; monitor patient. - Hormonal contraceptives: no known interaction but observe for unexpected symptoms. - Vaccines: no documented interaction, but maintain routine immunisation schedule.